nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.01.2010 | Original Article

Validation of cardiac ¹²³I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET

verfasst von: Kenji Ishibashi, Yuko Saito, Shigeo Murayama, Kazutomi Kanemaru, Keiichi Oda, Kiichi Ishiwata, Hidehiro Mizusawa, Kenji Ishii

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the diagnostic potential of cardiac ¹²³I-labelled metaiodobenzylguanidine (¹²³I-MIBG) scintigraphy in idiopathic Parkinson’s disease (PD). The diagnosis was confirmed by positron emission tomography (PET) imaging with ¹¹C-labelled 2β-carbomethoxy-3β-(4-fluorophenyl)-tropane (¹¹C-CFT) and ¹¹C-raclopride (together designated as dopamine PET).

Methods

Cardiac ¹²³I-MIBG scintigraphy and dopamine PET were performed for 39 parkinsonian patients. To estimate the cardiac ¹²³I-MIBG uptake, heart to mediastinum (H/M) ratios in early and delayed images were calculated. On the basis of established clinical criteria and our dopamine PET findings, 24 patients were classified into the PD group and 15 into the non-PD (NPD) group.

Results

Both early and delayed images showed that the H/M ratios were significantly lower in the PD group than in the NPD group. When the optimal cut-off levels of the H/M ratio were set at 1.95 and 1.60 in the early and delayed images, respectively, by receiver-operating characteristic analysis, the sensitivity of cardiac ¹²³I-MIBG scintigraphy for the diagnosis of PD was 79.2 and 70.8% and the specificity was 93.3 and 93.3% in the early and delayed images, respectively. In the Hoehn and Yahr 1 and 2 PD patients, the sensitivity decreased by 69.2 and 53.8% in the early and delayed images, respectively.

Conclusion

In early PD cases, cardiac ¹²³I-MIBG scintigraphy is of limited value in the diagnosis, because of its relatively lower sensitivity. However, because of its high specificity for the overall cases, cardiac ¹²³I-MIBG scintigraphy may assist in the diagnosis of PD in a complementary role with the dopaminergic neuroimaging.

Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:189–94.CrossRefPubMed

Satoh A, Serita T, Seto M, Tomita I, Satoh H, Iwanaga K, et al. Loss of 123I-MIBG uptake by the heart in Parkinson’s disease: assessment of cardiac sympathetic denervation and diagnostic value. J Nucl Med 1999;40:371–5.PubMed

Taki J, Nakajima K, Hwang EH, Matsunari I, Komai K, Yoshita M, et al. Peripheral sympathetic dysfunction in patients with Parkinson’s disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med 2000;27:566–73.CrossRefPubMed

Takatsu H, Nishida H, Matsuo H, Watanabe S, Nagashima K, Wada H, et al. Cardiac sympathetic denervation from the early stage of Parkinson’s disease: clinical and experimental studies with radiolabeled MIBG. J Nucl Med 2000;41:71–7.PubMed

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:249–51.CrossRefPubMed

Hamada K, Hirayama M, Watanabe H, Kobayashi R, Ito H, Ieda T, et al. Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson’s disease. J Neurol Neurosurg Psychiatry 2003;74:423–6.CrossRefPubMed

Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking CH. Cardiac uptake of [123I]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53:1020–5.PubMed

Raffel DM, Koeppe RA, Little R, Wang CN, Liu S, Junck L, et al. PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. J Nucl Med 2006;47:1769–77.PubMed

Rajput AH, Rozdilsky B, Rajput A. Accuracy of clinical diagnosis in parkinsonism–a prospective study. Can J Neurol Sci 1991;18:275–8.PubMed

10.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.CrossRefPubMed

11.

Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol 2000;57:369–72.CrossRefPubMed

12.

Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 2001;57:1497–9.PubMed

13.

Plotkin M, Amthauer H, Klaffke S, Kuhn A, Ludemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients. J Neural Transm 2005;112:677–92.CrossRefPubMed

14.

Nurmi E, Bergman J, Eskola O, Solin O, Vahlberg T, Sonninen P, et al. Progression of dopaminergic hypofunction in striatal subregions in Parkinson’s disease using [18F]CFT PET. Synapse 2003;48:109–15.CrossRefPubMed

15.

Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, et al. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson’s disease. Ann Neurol 1993;34:423–31.CrossRefPubMed

16.

Rinne JO, Ruottinen H, Bergman J, Haaparanta M, Sonninen P, Solin O. Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:737–41.CrossRefPubMed

17.

Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson’s disease: influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994;44:1325–9.PubMed

18.

Kaasinen V, Ruottinen HM, Någren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson’s disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone. J Nucl Med 2000;41:65–70.PubMed

19.

Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson’s disease. Mov Disord 1993;8:134–8.CrossRefPubMed

20.

Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, et al. Striatal D2 dopamine receptor status in Parkinson’s disease: an [18F]dopa and [11C]raclopride PET study. Mov Disord 1999;14:1025–30.CrossRefPubMed

21.

Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997;12:33–8.CrossRefPubMed

22.

Wang J, Zuo CT, Jiang YP, Guan YH, Chen ZP, Xiang JD, et al. 18F-FP-CIT PET imaging and SPM analysis of dopamine transporters in Parkinson’s disease in various Hoehn & Yahr stages. J Neurol 2007;254:185–90.CrossRefPubMed

23.

Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004;31:1631–8.CrossRefPubMed

24.

Kim YJ, Ichise M, Ballinger JR, Vines D, Erami SS, Tatschida T, et al. Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. Mov Disord 2002;17:303–12.CrossRefPubMed

25.

Verstappen CC, Bloem BR, Haaxma CA, Oyen WJ, Horstink MW. Diagnostic value of asymmetric striatal D2 receptor upregulation in Parkinson’s disease: an [123I]IBZM and [123I]FP-CIT SPECT study. Eur J Nucl Med Mol Imaging 2007;34:502–7.CrossRefPubMed

26.

Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al. Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 1997;11:307–13.CrossRefPubMed

27.

Hashimoto M, Kawasaki K, Suzuki M, Mitani K, Murayama S, Mishina M, et al. Presynaptic and postsynaptic nigrostriatal dopaminergic functions in multiple system atrophy. Neuroreport 2008;19:145–50.CrossRefPubMed

28.

Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2-like receptors in human striatum. Synapse 2009;63:282–90.CrossRefPubMed

29.

NK LO, Dolle F, Lundkvist C, Sandell J, Swahn CG, Vaufrey F, et al. Precursor synthesis and radiolabelling of the dopamine D2 receptor ligand [11C]raclopride from [11C]methyl triflate. J Labelled Compd Radiopharm 1999;42:1183–93.CrossRef

30.

Kawamura K, Oda K, Ishiwata K. Age-related changes of the [11C]CFT binding to the striatal dopamine transporters in the Fischer 344 rats: a PET study. Ann Nucl Med 2003;17:249–53.CrossRefPubMed

31.

Antonini A, Leenders KL, Reist H, Thomann R, Beer HF, Locher J. Effect of age on D2 dopamine receptors in normal human brain measured by positron emission tomography and 11C-raclopride. Arch Neurol 1993;50:474–80.PubMed

32.

Nakajima K, Taki J, Tonami N, Hisada K. Decreased 123I-MIBG uptake and increased clearance in various cardiac diseases. Nucl Med Commun 1994;15:317–23.CrossRefPubMed

33.

Gilman S, Low PA, Quinn N, Albanese A, Ben-Shlomo Y, Fowler CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Auton Nerv Syst 1998;74:189–92.PubMed

34.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.PubMed

35.

Li ST, Dendi R, Holmes C, Goldstein DS. Progressive loss of cardiac sympathetic innervation in Parkinson’s disease. Ann Neurol 2002;52:220–3.CrossRefPubMed

36.

Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res 2001;11:351–5.CrossRefPubMed

37.

Spiegel J, Mollers MO, Jost WH, Fuss G, Samnick S, Dillmann U, et al. FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov Disord 2005;20:552–61.CrossRefPubMed

38.

Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: substantia nigra regional selectivity. Brain 1991;114(Pt 5):2283–301.CrossRefPubMed

39.

Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW. Dopamine D2 receptor density remains constant in treated Parkinson’s disease. Ann Neurol 1986;19:487–92.CrossRefPubMed

40.

Bokobza B, Ruberg M, Scatton B, Javoy-Agid F, Agid Y. [3H]spiperone binding, dopamine and HVA concentrations in Parkinson’s disease and supranuclear palsy. Eur J Pharmacol 1984;99:167–75.CrossRefPubMed

41.

Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson’s disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876–80.PubMed

Titel: Validation of cardiac 123I-MIBG scintigraphy in patients with Parkinson’s disease who were diagnosed with dopamine PET
verfasst von: Kenji Ishibashi
Yuko Saito
Shigeo Murayama
Kazutomi Kanemaru
Keiichi Oda
Kiichi Ishiwata
Hidehiro Mizusawa
Kenji Ishii
Publikationsdatum: 01.01.2010
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2010
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-009-1202-1

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2010

68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma

PROLARA: prognosis-based lifetime attributable risk approximation for cancer from diagnostic radiation exposure

The impact of reconstruction method on the quantification of DaTSCAN images

New starch-based radiotracer for lung perfusion scintigraphy

Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation

Increased uptake of 131I-MIBG after intra-arterial application in liver metastases of a neuroendocrine tumor